16 minutes | Mar 28th 2018

Similar performance of Humira and BI695501 biosimilar in active rheumatoid arthritis

The switch from Humira to BI 695501 had no impact on efficacy, safety and immunogenicity in patients with moderately to severely active rheumatoid arthritis, according to a study recently published by ARD and discussed in this short podcast. Professor Stanley Cohen (Metroplex Clinical Research Center, Dallas, Texas, USA) tells ARD’s social media advisor Elena Nikiphorou (clinical researcher at King’s College London, UK) how the conclusions should have an important economic impact, particularly in less favoured clinical settings in the world.

Read the full paper on the Annals of the Rheumatic Diseases website: http://dx.doi.org/10.1136/annrheumdis-2017-212245.

Play Next
Mark Played